Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldebellizumab + carboplatin + etoposide + fluzoparil
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen is being investigated for the maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) following first-line induction. It consists of the PD-L1 inhibitor aldebellizumab, the PARP inhibitor fluzoparil, and the standard chemotherapy agents carboplatin and etoposide. Aldebellizumab (SHR-1316) is a humanized monoclonal antibody that blocks the interaction between PD-L1 and PD-1, enhancing the anti-tumor immune response. Fluzoparil (SHR3162) is a potent PARP1/2 inhibitor that induces synthetic lethality in cells with DNA repair deficiencies. The combination aims to leverage the synergistic effects of immunotherapy, chemotherapy, and PARP inhibition to improve clinical outcomes in ES-SCLC.
- Other names
- aldebellizumab + carboplatin + etoposide + fluzoparil
02
Targets
PARP3 (Poly(adp-ribose) polymerase 3)CD274 (Programmed cell death protein 1 ligand 1)DNATOP2A (DNA topoisomerase II)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on aldebellizumab + carboplatin + etoposide + fluzoparil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldebellizumab + carboplatin + etoposide + fluzoparil.